|
|
Blood, 1 August 2004, Vol. 104, No. 3, pp. 840-846.
Prepublished online as a Blood First Edition Paper on April 8, 2004; DOI 10.1182/blood-2003-10-3719.
 Previous Article | Table of Contents | Next Article 
RED CELLS
Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin
Anna Solovey,
Rahn Kollander,
Arun Shet,
Liming C. Milbauer,
Stephana Choong,
Angela Panoskaltsis-Mortari,
Bruce R. Blazar,
Robert J. Kelm, Jr, and
Robert P. Hebbel
From the Vascular Biology Center and Divisions of Hematology-Oncology-Transplantation, Departments of Medicine and Pediatrics, University of Minnesota Medical School, Minneapolis, MN; and Department of Medicine, University of Vermont, Colchester, VT.
Abnormal tissue factor (TF) expression has been demonstrated on blood monocytes and circulating endothelial cells in humans with sickle cell anemia. We have now studied sickle transgenic mice to help define the biology of endothelial TF expression in sickle disease. Using immunostaining of tissue sections, we find that this is confined almost exclusively to the pulmonary veins. About 15% and 13% of these exhibit TF-positive endothelium in the wild-type normal mouse and the normal human hemoglobin (HbA)–expressing control transgenic mouse, respectively. The mild sickle mouse is indistinguishable from normal ( 14% positive), but TF expression is significantly elevated in the moderate and severe mouse models of sickle disease ( 29% and 41% positive, respectively). Exposure of the mild sickle mouse to hypoxia for 3 hours, followed by reoxygenation, converted its TF expression phenotype to that of the severe sickle mouse ( 36% positive). Pretreatment with lovastatin eliminated excessive expression of TF in the posthypoxic mild sickle mouse ( 16% positive) and in the more severe mouse at ambient air ( 21% positive). In addition to identifying tissue expression of endothelial TF in the sickle lung, these studies implicate reperfusion injury physiology in its expression and suggest a rationale for use of statins in sickle disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
The chicken or the egg? Tissue factor and inflammation in sickle cell disease
- Cheryl A. Hillery
Blood 2004 104: 595-596.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
L. De Franceschi, O. S. Platt, G. Malpeli, A. Janin, A. Scarpa, C. Leboeuf, Y. Beuzard, E. Payen, and C. Brugnara
Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice
FASEB J,
June 1, 2008;
22(6):
1849 - 1860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Ataga, C. G. Moore, C. A. Hillery, S. Jones, H. C. Whinna, D. Strayhorn, C. Sohier, A. Hinderliter, L. V. Parise, and E. P. Orringer
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension
Haematologica,
January 1, 2008;
93(1):
20 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ghosh, H. Wang, Y. Ai, E. Romeo, J. P. Luyendyk, J. M. Peters, N. Mackman, S. K. Dey, and T. Hla
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPAR{delta} activation
J. Exp. Med.,
September 3, 2007;
204(9):
2053 - 2061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mackman, R. E. Tilley, and N. S. Key
Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2007;
27(8):
1687 - 1693.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Lunzer, A. Yekkirala, R. P. Hebbel, and P. S. Portoghese
Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia
PNAS,
April 3, 2007;
104(14):
6061 - 6065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. C. Aird
Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms
Circ. Res.,
February 2, 2007;
100(2):
158 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Telen
Role of Adhesion Molecules and Vascular Endothelium in the Pathogenesis of Sickle Cell Disease
Hematology,
January 1, 2007;
2007(1):
84 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Ataga and N. S. Key
Hypercoagulability in Sickle Cell Disease: New Approaches to an Old Problem
Hematology,
January 1, 2007;
2007(1):
91 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. Kim, V. Rajagopal, C. Gonsalves, C. Johnson, and V. K. Kalra
A Novel Role of Hypoxia-Inducible Factor in Cobalt Chloride- and Hypoxia-Mediated Expression of IL-8 Chemokine in Human Endothelial Cells
J. Immunol.,
November 15, 2006;
177(10):
7211 - 7224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Rong, F. Hu, R. Huang, N. Mackman, J. M. Horowitz, R. L. Jensen, D. L. Durden, E. G. Van Meir, and D. J. Brat
Early Growth Response Gene-1 Regulates Hypoxia-Induced Expression of Tissue Factor in Glioblastoma Multiforme through Hypoxia-Inducible Factor-1-Independent Mechanisms.
Cancer Res.,
July 15, 2006;
66(14):
7067 - 7074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Lee, K. I. Ataga, E. P. Orringer, D. R. Phillips, and L. V. Parise
Biologically Active CD40 Ligand Is Elevated in Sickle Cell Anemia: Potential Role for Platelet-Mediated Inflammation
Arterioscler. Thromb. Vasc. Biol.,
July 1, 2006;
26(7):
1626 - 1631.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Hebbel, R. Kollander, A. Solovey, S. Choong, and R. J. Kelm Jr.
Therapeutic Inhibition of Endothelial Cell Tissue Factor Expression In Vivo by Nitric Oxide and Arginine in Sickle Transgenic Mice.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
210 - 210.
[Abstract]
|
|
|
|
|
|
|
A. M. Hanash and R. B. Levy
Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation
Blood,
February 15, 2005;
105(4):
1828 - 1836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Buchanan, M. R. DeBaun, C. T. Quinn, and M. H. Steinberg
Sickle Cell Disease
Hematology,
January 1, 2004;
2004(1):
35 - 47.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
